CYTOKINE-PRODUCING RESOURCE OF IMMUNOCOMPETENT BLOOD CELLS IN BREAST TUMORS AND PRECANCEROUS CHANGES OF MAMMARY GLAND

At present, only ductal carcinoma in situ is included into the group of precancerous lesions of mammary ducts, according to International Agency for the Study of Cancer. However, based on recent publications, in addition to ductal carcinoma in situ, sclerosing adenosis, intraductal proliferative lesions and radial scar may be also attributed to precancerous changes. A variety of both benign and malignant events in mammary gland, the features of neoplastic growth and age of the patients require new approaches to study of carcinogenic events in mammary gland. As based on the known role of cytokines in genesis of malignancies, the aim of the study was to evaluate the cytokine-producing resource of immunocompetent blood cells in malignant, benign and precancerous mammary disorders. To assess the cytokine-producing resource of immunocompetent blood cells in the patients, we studied quantitative effects of polyclonal activators upon production of cytokines by immunocompetent blood cells of patients with invasive ductal cancer representing a histological type of adenocarcinoma (group I), and patients with non-malignant breast neoplasias (group II). At subsequent step, the patients with non-malignant neoplasms of the breast were divided into a subgroup of patients with only fibroadenoma and mastopathy (group III), and a group which included patients with precancerous diseases, i.e., sclerosing adenosis and interductal proliferates (group IV). Concentrations of IL-2, IL-6, IL-8, IL-10, IL-17, IL-18, IL-1β, IL-1ra, TNFα, IFNγ, G-CSF, GM-CSF, VEGF, and MCP-1 were determined by solid-phase enzyme immunoassay. When comparing groups I and II, we revealed higher influence of polyclonal activators upon production of G-CSF and GM-CSF in patients with invasive ductal cancer. When comparing the influence of polyclonal activation for cytokine production in patients of I and III groups, higher values were registered in patients with invasive ductal cancer (production of IL-2, G-CSF, and GM-CSF), and in patients with fibroadenoma and mastopathy (IL-18, and TNFαproduction). When comparing patients of groups I and IV, higher indexes of the polyclonal activator effects were found only for IL-1ra, G-CSF, and VEGF production in invasive ductal cancer. When comparing the indexes of polyclonal activator influence upon cytokine production of groups III and IV, higher values were obtained in patients with benign changes for the following cytokines: IL-8, IL-18, IL-1β, IL-1ra and TNFα, in contrast to patients with sclerosing adenosis and proliferates. The lower indexes of polyclonal activating effects upon the production of a number of cytokines in patients with precancerous changes, as compared to patients with malignant and benign breast tumors, do not indicate a decreased functional activity of immunocompetent blood cells. However, those may be due to high level of spontaneous cytokine production in sclerosing adenosis and interductal proliferates.

1. Sosnina A.V., Velikaya N.V., Varaksin N.A., Grishaev M.P., Autenshlyus A.I. The role of cytokines in the pathogenesis of malignant neoplasms. Novosibirsk: Ofset, 2014. 128 p.

2. Aroner S.A., Collins L.C., Connolly J.L., Colditz G.A., Schnitt S.J., Rosner B.A., Hankinson S.E., Tamimi R.M. Radial scars and subsequent breast cancer risk: results from the Nurses’ Health Studies. Breast Cancer Res. Treat., 2013, Vol. 1, no. 139, pp. 277-285.

3. Burchill M.A., Yang J., Vang K.B., Farrar M.A. Interleukin‑2 receptor signaling in regulatory T cell development and homeostasis.Immunol. Lett., 2007, Vol. 1, no. 114, pp. 1-8.

4. Castells X., Domingo L., Corominas J.M., Torá‑Rocamora I., Quintana M.J., Baré M., Vidal C., Natal C., Sánchez M., Saladié F., Ferrer J., Vernet M., Servitja S., Rodríguez‑Arana A., Roman M., Espinàs J.A., Sala M. Breast cancer risk after diagnosis by screening mammography of nonproliferative or proliferative benign breast disease: a study from a population‑based screening program. Breast Cancer Res. Treat., 2015, Vol. 1, no. 149, pp. 237-244.

5. Chavey C., Bibeau F., Gourgou‑Bourgade S., Burlinchon S., Boissière F., Laune D., Roques S., Lazennec G. Oestrogen receptor negative breast cancers exhibit high cytokine content. Breast Cancer Res., 2007, Vol. 1, no. 9, pp. 1-11.

6. Chen Y., Zhao Z., Chen Y., Lv Z., Ding X., Wang R., Xiao H., Hou C., Shen B., Feng J., Guo R., Li Y., Peng H., Han G., Chen G. An epithelial‑to‑mesenchymal transition‑inducing potential of granulocyte macrophage colony stimulating factor in colon cancer. Sci. Rep., 2017, Vol. 1, no. 7, pp. 1-12.

7. Cote M.L., Ruterbusch J. J., Alosh B., Bandyopadhyay S., Kim E., Albashiti B., Sharaf Aldeen B., Radisky D.C., Frost M.H., Visscher D.W., Hartmann L.C., Nassar W.H., Ali‑Femhi R. Benign breast disease and the risk of subsequent breast cancer in African American women. Cancer Prev. Res. (Phila)., 2012, Vol. 12, no. 5, pp. 1375-1380.

8. Degnim A.C., Nassar A., Stallings‑Mann M., Keith Anderson S., Oberg A.L., Vierkant R.A., Frank R.D., Wang C., Winham S.J., Frost M.H., Hartmann L.C., Visscher D.W., Radisky D.C. Gene signature model for breast cancer risk prediction for women with sclerosing adenosis. Breast Cancer Res. Treat., 2015, Vol. 3, no. 152, pp. 687-694.

9. Degnim A.C., Visscher D.W., Berman H.K., Frost M.H., Sellers T.A., Vierkant R.A., Maloney S.D., Pankratz V.S., de Groen P.C., Lingle W.L., Ghosh K., Penheiter L., Tlsty T., Melton L.J. 3rd, Reynolds C.A., Hartmann L.C. Stratification of breast cancer risk in women with atypia: a Mayo cohort study. J. Clin. Oncol., 2007, Vol. 19, no. 25, pp. 2671-2677.

10. Dinarello C.A. Why not treat human cancer with interleukin‑1 blockade? Cancer Metastasis Rev., 2010, Vol. 2, no. 29, pp. 317-329.

11. Hartmann L.C., Sellers T.A., Frost M.H., Lingle W.L., Degnim A.C., Ghosh K., Vierkant R.A., Maloney S.D., Pankratz V.S., Hillman D.W., Suman V.J., Johnson J., Blake C., Tlsty T., Vachon C.M., Melton L.J. 3 rd , Visscher D.W. Benign breast disease and the risk of breast cancer. N. Engl. J. Med., 2005, Vol. 3, no. 353, pp. 229-237.

12. Kim K.E., Song H., Kim T.S., Yoon D., Kim C.W., Bang S.I., Hur D.Y., Park H., Cho D.H. Interleukin 18 is a critical factor for vascular endothelial growth factor‑enhanced migration in human gastric cancer cell lines. Oncogene, 2007, Vol. 10, no. 26, pp. 1468-1476.

13. Lalla R.V., Boisoneau D.S., Spiro J.D., Kreutzer D.L. Expression of vascular endothelial growth factor receptors on tumor cells in head and neck squamous cell carcinoma. Arch. Otolaryngol. Head Neck Surg., 2003, Vol. 8, no. 129, pp. 882-888.

14. Lewis A.M., Varghese S., Xu H., Alexander H.R. Interleukin‑1 and cancer progression: the emerging role of interleukin‑1 receptor antagonist as a novel therapeutic agent in cancer treatment. J. Transl. Med., 2006, Vol. 4, no. 48, pp. 1-12.

15. Morrow M., Schnitt S.J., Norton L. Current management of lesions associated with an increased risk of breast cancer. Nat. Rev. Clin. Oncol., 2015, Vol. 4, no. 12, pp. 227-238.

16. Olejniczak K., Kasprzak A. Biological properties of interleukin 2 and its role in pathogenesis of selected diseases – a review. Med. Sci. Monit., 2008, Vol. 10, no. 14, pp. 179-189.

17. Visscher D.W., Nassar A., Degnim A.C., Frost M.H., Vierkant R.A., Frank R.D., Tarabishy Y., Radisky D.C., Hartmann L.C. Sclerosing adenosis and risk of breast cancer. Breast Cancer Res. Treat., 2014, Vol. 1, no. 144, pp. 205-212.